Z. Z. Mamedli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Z. Z. Mamedli has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Sergey S. Gordeyev
N.N. Blokhin National Medical Research Center of Oncology; Tyumen State Medical University
25 shared publications - Andrey V. Polynovskiy
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
12 shared publications - Alexey A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
10 shared publications V. A. Aliev
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
10 shared publications- Dmitrii V. Kuzmichev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
8 shared publications - Mikhail Yu. Fedyanin
Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center
8 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (3) , 19-31
Functional contribution of the left colic artery to perfusion of the colorectal anastomotic site: a paired intraoperative study using quantitative indocyanine green fluorescence angiography
Aim. To assess the functional contribution of the left colic artery (LCA) to perfusion of the proximal colon during resection of the left colon and rectum using quantitative indocyanine green (ICG) fluorescence angiography. Patients and Methods. This prospective single-centre pilot study included 40 patients with adenocarcinoma of the distal sigmoid colon, rectosigmoid junction or rectum who underwent laparoscopic resection with LCA preservation and primary colorectal anastomosis. Quantitative ICG fluorescence angiography was performed twice in each patient: during temporary clamping of the LCA and after restoration of LCA flow. The following parameters were measured: maximum fluorescence intensity at the planned resection site (Imax, % of a reference point), time to peak intensity (Tmax), and wash-in (Vin) and wash-out (Vout) indices of the fluorescence signal, for which lower values indicate faster kinetics. Measurements under the two conditions were compared using the Wilcoxon signed-rank test. Postoperative complications were recorded for 30 days, and anastomotic leakage was graded according to the International Study Group of Rectal Cancer (ISREC) criteria. Results. After restoration of LCA flow, median Imax increased from 90% (IQR 85–92%) to 94% (IQR 92.8–95%) (p 0.001). Imax increased in 35 patients (87.5%) and decreased in none. With the LCA clamped, Imax was below the 92% threshold in 26 patients (65.0%), compared with 2 (5.0%) after flow restoration. Restoration of flow was accompanied by a shortening of Tmax from 34 s (IQR 29–45) to 27 s (IQR 23–31.5), and by decreases in Vin from 0.70 (IQR 0.60–0.73) to 0.40 (IQR 0.40–0.50) arbitrary units (a.u.) and in Vout from 2.45 (IQR 1.98–2.70) to 2.05 (IQR 1.70–2.33) a.u. (all p 0.001), indicating faster wash-in and wash-out of the dye. Postoperative complications occurred in 7 patients (17.5%) and anastomotic leakage in 5 (12.5%): ISREC grade A in 1 and grade B in 4. Conclusion. Temporary clamping of the LCA significantly reduced fluorescence intensity and slowed ICG kinetics at the planned anastomotic site, indicating a substantial functional contribution of the LCA to perfusion of the proximal colon. Interruption of LCA flow, which simulates high ligation of the inferior mesenteric artery, reduced perfusion below the threshold in most patients. These findings support preservation of the LCA. Whether these perfusion changes are associated with anastomotic leakage should be investigated in a larger cohort.
- 26 October 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (3) , 19-31
Open AccessFunctional contribution of the left colic artery to perfusion of the colorectal anastomotic site: a paired intraoperative study using quantitative indocyanine green fluorescence angiography
Aim. To assess the functional contribution of the left colic artery (LCA) to perfusion of the proximal colon during resection of the left colon and rectum using quantitative indocyanine green (ICG) fluorescence angiography. Patients and Methods. This prospective single-centre pilot study included 40 patients with adenocarcinoma of the distal sigmoid colon, rectosigmoid junction or rectum who underwent laparoscopic resection with LCA preservation and primary colorectal anastomosis. Quantitative ICG fluorescence angiography was performed twice in each patient: during temporary clamping of the LCA and after restoration of LCA flow. The following parameters were measured: maximum fluorescence intensity at the planned resection site (Imax, % of a reference point), time to peak intensity (Tmax), and wash-in (Vin) and wash-out (Vout) indices of the fluorescence signal, for which lower values indicate faster kinetics. Measurements under the two conditions were compared using the Wilcoxon signed-rank test. Postoperative complications were recorded for 30 days, and anastomotic leakage was graded according to the International Study Group of Rectal Cancer (ISREC) criteria. Results. After restoration of LCA flow, median Imax increased from 90% (IQR 85–92%) to 94% (IQR 92.8–95%) (p 0.001). Imax increased in 35 patients (87.5%) and decreased in none. With the LCA clamped, Imax was below the 92% threshold in 26 patients (65.0%), compared with 2 (5.0%) after flow restoration. Restoration of flow was accompanied by a shortening of Tmax from 34 s (IQR 29–45) to 27 s (IQR 23–31.5), and by decreases in Vin from 0.70 (IQR 0.60–0.73) to 0.40 (IQR 0.40–0.50) arbitrary units (a.u.) and in Vout from 2.45 (IQR 1.98–2.70) to 2.05 (IQR 1.70–2.33) a.u. (all p 0.001), indicating faster wash-in and wash-out of the dye. Postoperative complications occurred in 7 patients (17.5%) and anastomotic leakage in 5 (12.5%): ISREC grade A in 1 and grade B in 4. Conclusion. Temporary clamping of the LCA significantly reduced fluorescence intensity and slowed ICG kinetics at the planned anastomotic site, indicating a substantial functional contribution of the LCA to perfusion of the proximal colon. Interruption of LCA flow, which simulates high ligation of the inferior mesenteric artery, reduced perfusion below the threshold in most patients. These findings support preservation of the LCA. Whether these perfusion changes are associated with anastomotic leakage should be investigated in a larger cohort.
- Open Access
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 88-98
Optimal timing of adjuvant chemotherapy initiation in colon cancer patients: real-world clinical practice data
Aim. To determine the optimal timing of adjuvant chemotherapy (ACT) initiation based on real-world clinical practice data and to assess factors influencing timely ACT initiation in patients with colon cancer (CC). Materials and methods. This study is a single-center retrospective cohort analysis. Patients with CC who received ACT between 2015 and 2023 were included. Uni- and multivariate analyses of factors affecting ACT initiation timing were performed. The threshold value for ACT initiation timing in relation to overall survival (OS) and recurrence-free survival (RFS) was evaluated using area under the curve (AUC) analysis. The frequency of completing more than 3 months of ACT depending on the surgical approach was also analyzed. Results. During the study period, 871 patients received ACT. A 6-week period was established as the threshold for CC progression risk. Five-year OS was 66.4 % in the group of patients who started ACT more than 6 weeks after surgery, and 81.5 % in the group who started treatment within 6 weeks of surgery. The differences in OS were significant (hazard ratio (HR) 0.532; 95 % confidence interval (CI) 0.360–0.787; p = 0.002). Significant differences were also found in 5-year RFS (HR 0.637; 95 % CI 0.447–0.908; p = 0.013): 61.8 % in the group starting ACT more than 6 weeks after surgery and 72.4 % with earlier initiation. Multivariate analysis showed that only the absence of postoperative complications influenced the likelihood of starting ACT within 6 weeks (HR 0.365; 95 % CI 0.140–0.955; p = 0.040). Conclusion. Optimal ACT initiation timing may be shorter than 8 weeks in real-world clinical practice. Minimally invasive surgery may improve patient adherence to the ACT regimen.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 88-98
Open AccessOptimal timing of adjuvant chemotherapy initiation in colon cancer patients: real-world clinical practice data
Aim. To determine the optimal timing of adjuvant chemotherapy (ACT) initiation based on real-world clinical practice data and to assess factors influencing timely ACT initiation in patients with colon cancer (CC). Materials and methods. This study is a single-center retrospective cohort analysis. Patients with CC who received ACT between 2015 and 2023 were included. Uni- and multivariate analyses of factors affecting ACT initiation timing were performed. The threshold value for ACT initiation timing in relation to overall survival (OS) and recurrence-free survival (RFS) was evaluated using area under the curve (AUC) analysis. The frequency of completing more than 3 months of ACT depending on the surgical approach was also analyzed. Results. During the study period, 871 patients received ACT. A 6-week period was established as the threshold for CC progression risk. Five-year OS was 66.4 % in the group of patients who started ACT more than 6 weeks after surgery, and 81.5 % in the group who started treatment within 6 weeks of surgery. The differences in OS were significant (hazard ratio (HR) 0.532; 95 % confidence interval (CI) 0.360–0.787; p = 0.002). Significant differences were also found in 5-year RFS (HR 0.637; 95 % CI 0.447–0.908; p = 0.013): 61.8 % in the group starting ACT more than 6 weeks after surgery and 72.4 % with earlier initiation. Multivariate analysis showed that only the absence of postoperative complications influenced the likelihood of starting ACT within 6 weeks (HR 0.365; 95 % CI 0.140–0.955; p = 0.040). Conclusion. Optimal ACT initiation timing may be shorter than 8 weeks in real-world clinical practice. Minimally invasive surgery may improve patient adherence to the ACT regimen.
- Open Access
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 118-125
Retroperitoneal end colostomy for prevention of parastomal hernia: single-center retrospective study
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 118-125
Open AccessRetroperitoneal end colostomy for prevention of parastomal hernia: single-center retrospective study
Background. Retroperitoneal end colostomy creation is a safe and effective method of parastomal hernia (PH) prevention. Aim. To investigate the rate of PH in patients after abdominoperineal resection of the rectum. To compare effects of retroperitoneal end colostomy created through laparoscopic and open accesses on PH prevention. Materials and methods. In the single-center study, incidence of PH was retrospectively analyzed in 110 patients who underwent abdominoperineal resection of the rectum between January of 2018 and December of 2024 due to rectal cancer, persistent or recurrent squamous cell carcinoma of the anal canal after chemoradiation therapy. PH was diagnosed using computed tomography with independent evaluation by an expert 1 or more years after the surgery. Patient characteristics, PH incidence, rate and severity of postoperative complications were compared in the groups of laparoscopic and open surgeries. Results. Median follow-up was 19.2 months in the group of extraperitoneal colostomy and 12.8 months in the group of transperitoneal colostomy. Statistically significant differences (р = 0.027) were found in the incidence of hernias 1 and more years after surgery in the laparoscopic surgery group: hernias developed in 5 (14.3 %; 95 % confidence interval (CI) 48–29.8) patients with extraperitoneal colostomy and in 10 (40 %; 95 % CI 21.1–61.2) patients with transperitoneal colostomy. There were no significant differences in the rate of adverse events (р = 0.76). In the total group and group of open surgeries, no statistically significant differences were observed (р = 0.146): hernias developed in 10 (17.9 %; 95 % CI 8.8–30.5) patients with extraperitoneal colostomy and 16 (29.6 %; 95 % CI 17.9–42.4) patients with transperitoneal colostomy in the total group, in 5 (22.7 %; 95 % CI 8.3–45.4) patients with extraperitoneal stoma, and in 6 (20.7 %; 95 % CI 8.4–39.5) patients with transperitoneal stoma in the open surgery group. Conclusion. The results of our study do not demonstrate benefits of extraperitoneal colostomy using open access. However, the results show safety and efficacy of retroperitoneal end colostomy creation in laparoscopic abdominoperineal resection.
- Open Access
- 19 June 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (2) , 62-70
Association of serum galectin-3 levels in patients with key clinical and morphological characteristics of colorectal cancer
Introduction. Galectins are a family of β-galactoside-binding proteins involved in the regulation of cell adhesion, proliferation, apoptosis, and the immune response, playing a key role in carcinogenesis. Galectin-3 is the only chimeric protein of the galectin family, whose functional activity is determined by its ability to oligomerize. Increased expression of galectin-3 in tumor tissue and its high serum concentration are associated with colorectal cancer (CRC) progression. However, the clinical, morphological, and prognostic significance of serum galectin-3 levels in this disease remains poorly understood. Aim. To analyze the association of galectin-3 levels in the blood serum of patients with key clinical, morphological characteristics and prognosis of CRC. Materials and methods. A total of 210 previously untreated patients with CRC at various stages of the tumor were examined. These patients ranged in age from 31 to 75 years (114 men and 96 women). The control group consisted of 32 healthy donors aged 31 to 67 years (20 women and 12 men). The clinical diagnosis in all patients was confirmed by tumor morphological examination according to the International Histological Classification of Tumors of the Digestive Tract of the World Health Organization (2019). All patients were diagnosed with colon adenocarcinoma of varying degrees of differentiation. Galectin-3 concentrations were determined in serum collected using a standard method before the start of specific treatment using the Human Galectin-3 Quantikine ELISA reagents (RD Systems, USA) according to the manufacturer’s instructions. Measurements were performed on a BEP 2000 Advance automated enzyme-linked immunosorbent assay (Siemens Healthcare Diagnostics, Germany). Marker levels were expressed as nanograms (ng) per 1 ml of serum. The nonparametric Mann–Whitney and Kruskal–Wallis tests were used to compare parameters and analyze their relationships. Overall survival was analyzed using the Kaplan–Meier method and the nonparametric Cox proportional hazards model. Differences and correlations were considered statistically significant at p 0.05. Results. Enzyme-linked immunosorbent assay revealed that baseline pre-treatment serum galectin-3 levels in 210 previously untreated CRC patients ranged widely from 2.6 to 24.7 ng / ml, and the median level (10.7 ng / ml) was statistically significantly higher than that in 32 healthy control donors (8.6 ng / ml) (p = 0.004). ROC analysis data do not support the use of serum galectin-3 levels in the diagnosis of CRC (test sensitivity 39 %, specificity 94 %). The study did not reveal any significant associations between galectin-3 levels and the main clinical and morphological characteristics of CRC. Univariate analysis and Cox regression analysis of galectin-3 levels revealed an unfavorable prognostic significance of this protein in patients with CRC (p = 0.0006 and p = 0.0001, respectively). Conclusion. A statistically significant increase in serum galectin-3 concentrations was observed in patients with colorectal cancer compared to healthy donors. Despite the lack of associations with clinical and morphological characteristics of the tumor, elevated baseline serum galectin-3 levels in patients with colorectal cancer are significantly associated with a poor overall survival prognosis.
- 19 June 2026
- Published by Publishing House ABV Press in Advances in molecular oncology
- Vol. 13 (2) , 62-70
Open AccessAssociation of serum galectin-3 levels in patients with key clinical and morphological characteristics of colorectal cancer
Introduction. Galectins are a family of β-galactoside-binding proteins involved in the regulation of cell adhesion, proliferation, apoptosis, and the immune response, playing a key role in carcinogenesis. Galectin-3 is the only chimeric protein of the galectin family, whose functional activity is determined by its ability to oligomerize. Increased expression of galectin-3 in tumor tissue and its high serum concentration are associated with colorectal cancer (CRC) progression. However, the clinical, morphological, and prognostic significance of serum galectin-3 levels in this disease remains poorly understood. Aim. To analyze the association of galectin-3 levels in the blood serum of patients with key clinical, morphological characteristics and prognosis of CRC. Materials and methods. A total of 210 previously untreated patients with CRC at various stages of the tumor were examined. These patients ranged in age from 31 to 75 years (114 men and 96 women). The control group consisted of 32 healthy donors aged 31 to 67 years (20 women and 12 men). The clinical diagnosis in all patients was confirmed by tumor morphological examination according to the International Histological Classification of Tumors of the Digestive Tract of the World Health Organization (2019). All patients were diagnosed with colon adenocarcinoma of varying degrees of differentiation. Galectin-3 concentrations were determined in serum collected using a standard method before the start of specific treatment using the Human Galectin-3 Quantikine ELISA reagents (RD Systems, USA) according to the manufacturer’s instructions. Measurements were performed on a BEP 2000 Advance automated enzyme-linked immunosorbent assay (Siemens Healthcare Diagnostics, Germany). Marker levels were expressed as nanograms (ng) per 1 ml of serum. The nonparametric Mann–Whitney and Kruskal–Wallis tests were used to compare parameters and analyze their relationships. Overall survival was analyzed using the Kaplan–Meier method and the nonparametric Cox proportional hazards model. Differences and correlations were considered statistically significant at p 0.05. Results. Enzyme-linked immunosorbent assay revealed that baseline pre-treatment serum galectin-3 levels in 210 previously untreated CRC patients ranged widely from 2.6 to 24.7 ng / ml, and the median level (10.7 ng / ml) was statistically significantly higher than that in 32 healthy control donors (8.6 ng / ml) (p = 0.004). ROC analysis data do not support the use of serum galectin-3 levels in the diagnosis of CRC (test sensitivity 39 %, specificity 94 %). The study did not reveal any significant associations between galectin-3 levels and the main clinical and morphological characteristics of CRC. Univariate analysis and Cox regression analysis of galectin-3 levels revealed an unfavorable prognostic significance of this protein in patients with CRC (p = 0.0006 and p = 0.0001, respectively). Conclusion. A statistically significant increase in serum galectin-3 concentrations was observed in patients with colorectal cancer compared to healthy donors. Despite the lack of associations with clinical and morphological characteristics of the tumor, elevated baseline serum galectin-3 levels in patients with colorectal cancer are significantly associated with a poor overall survival prognosis.
- Open Access
- 5 June 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (2) , 128-134
Desmoid fibromatosis of the pelvis originating from a J-pouch of small bowel (case report)
This clinical case presents a successful treatment experience in a young patient with a large desmoid tumor and familial adenomatous polyposis syndrome, previously operated on for rectal cancer with proctocolectomy. OBJECTIVE: to analyze the epidemiology and pathophysiology of the disease and evaluate the tactics of working with this pathology, we reviewed the global medical literature, the patient's anamnestic data, the results of diagnostics and intraoperative decisions, and the results of histological examination of the surgical specimen. PATIENTS AND METHODS: patient K., 28, presented as part of the dynamic monitoring of her primary oncological disease in February 2022. Rectal cancer at 5 cm cT2N0M0 (urTisN0M0), ARS syndrome, histologically — intestinaltype adenocarcinoma and abdominal discomfort not relieved by analgesics. In April 2022, she underwent chemoradiation therapy with preliminary ovarian transposition, followed by a proctocolectomy with the creation of a pelvic small bowel pouch. In March 2024, she became pregnant naturally, delivering a healthy baby via cesarean section. In April 2025, during oncology monitoring, a 6 cm diameter pelvic mass was detected, which, according to CT and MRI, reached 13.5 cm in diameter four months later. An ultrasound-guided puncture was performed for histological confirmation, and the diagnosis was desmoid fibromatosis. A consultation was held, and the decision was made to remove the desmoid tumor and perform an obstructive resection of the pouch. RESULTS: an analysis of the literature on the practical aspects of treating this pathology was conducted, highlighting the need to develop standardized clinical guidelines for the prevention, diagnosis, and treatment of intra-abdominal desmoids due to the unpredictable course of this disease and the lack of clearly established patient management concepts. CONCLUSION: this clinical case is notable for its rare occurrence of a desmoid tumor, poorly studied in the medical community, which arose in a young patient diagnosed with familial adenomatous polyposis and the fact of a spontaneous pregnancy following pelvic radiation therapy and extensive surgical intervention.
- 5 June 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (2) , 128-134
Open AccessDesmoid fibromatosis of the pelvis originating from a J-pouch of small bowel (case report)
This clinical case presents a successful treatment experience in a young patient with a large desmoid tumor and familial adenomatous polyposis syndrome, previously operated on for rectal cancer with proctocolectomy. OBJECTIVE: to analyze the epidemiology and pathophysiology of the disease and evaluate the tactics of working with this pathology, we reviewed the global medical literature, the patient's anamnestic data, the results of diagnostics and intraoperative decisions, and the results of histological examination of the surgical specimen. PATIENTS AND METHODS: patient K., 28, presented as part of the dynamic monitoring of her primary oncological disease in February 2022. Rectal cancer at 5 cm cT2N0M0 (urTisN0M0), ARS syndrome, histologically — intestinaltype adenocarcinoma and abdominal discomfort not relieved by analgesics. In April 2022, she underwent chemoradiation therapy with preliminary ovarian transposition, followed by a proctocolectomy with the creation of a pelvic small bowel pouch. In March 2024, she became pregnant naturally, delivering a healthy baby via cesarean section. In April 2025, during oncology monitoring, a 6 cm diameter pelvic mass was detected, which, according to CT and MRI, reached 13.5 cm in diameter four months later. An ultrasound-guided puncture was performed for histological confirmation, and the diagnosis was desmoid fibromatosis. A consultation was held, and the decision was made to remove the desmoid tumor and perform an obstructive resection of the pouch. RESULTS: an analysis of the literature on the practical aspects of treating this pathology was conducted, highlighting the need to develop standardized clinical guidelines for the prevention, diagnosis, and treatment of intra-abdominal desmoids due to the unpredictable course of this disease and the lack of clearly established patient management concepts. CONCLUSION: this clinical case is notable for its rare occurrence of a desmoid tumor, poorly studied in the medical community, which arose in a young patient diagnosed with familial adenomatous polyposis and the fact of a spontaneous pregnancy following pelvic radiation therapy and extensive surgical intervention.
- Open Access
- 5 June 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (2) , 27-37
Quantitative assessment of intraoperative perfusion using fluorescence imaging for the prevention of anastomotic leakage in colorectal surgery: first experience
AIM: to evaluate discrepancies between subjective intraoperative perfusion assessment and qualitative and quantitative ICG fluorescence angiography, as well as the impact of quantitative perfusion assessment on intraoperative surgical decision-making during colorectal resections. PATIENTS AND METHODS: this prospective single-center study included patients aged 18 years and older with histologically confirmed adenocarcinoma of the distal sigmoid colon, rectosigmoid junction, or rectum, who underwent surgery with primary colorectal anastomosis between May and November 2025. No restrictions regarding tumor stage were applied. Intraoperatively, fluorescence angiography with ICG (0.1 mg/kg) was performed. Perfusion was assessed using the UFF-630/675-01-BIOSPEC system with quantitative analysis of fluorescence parameters, including maximum intensity (Imax), time to peak intensity (Tmax), inflow rate, and outflow rate. The primary outcome was the frequency of discrepancies between visual, qualitative, and quantitative perfusion assessment of the colonic wall. Postoperative complications were recorded within 30 days and classified according to the Clavien-Dindo classification, while anastomotic leakage was graded according to the ISREC classification. RESULTS: a total of 20 patients were included in the study. Impaired colonic wall perfusion was identified in 3/20 (15%) patients based on visual assessment, in 3/20 (15%) patients based on qualitative ICG assessment, whereas quantitative analysis revealed signs of reduced perfusion in 6/20 (30%) patients. Subjective perfusion assessment was based on visual signs of blood supply. The presence of bright red bleeding and a visibly pulsatile blood jet were evaluated. The presence of bright red blood alone was considered a doubtful finding, whereas a pulsatile jet of bright red blood was interpreted as a positive result. In the absence of these signs, additional bowel resection was performed prior to ICG assessment. Thus, a discrepancy between subjective visual and quantitative perfusion assessment was observed in 3/20 (15%) patients, and a similar discrepancy between qualitative ICG assessment and quantitative analysis was also observed in 3/20 (15%) patients. Anastomotic leakage occurred in 2/20 (10%) patients, including 1/20 (5%) case of grade A and 1/20 (5%) case of grade B according to the ISREC classification. In both patients, a decrease in Imax to 83% and 87%, respectively, was observed. In one of these patients, visual perfusion assessment was considered adequate, whereas qualitative ICG assessment was classified as weakly positive in both cases. Negative visual and qualitative perfusion assessments were consistent with quantitative findings in 2/20 (10%) patients. CONCLUSION: the preliminary data demonstrate the presence of discrepancies between subjective, qualitative, and quantitative assessment of intestinal wall perfusion. The clinical significance of these findings should be further evaluated in larger prospective studies.
- 5 June 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (2) , 27-37
Open AccessQuantitative assessment of intraoperative perfusion using fluorescence imaging for the prevention of anastomotic leakage in colorectal surgery: first experience
AIM: to evaluate discrepancies between subjective intraoperative perfusion assessment and qualitative and quantitative ICG fluorescence angiography, as well as the impact of quantitative perfusion assessment on intraoperative surgical decision-making during colorectal resections. PATIENTS AND METHODS: this prospective single-center study included patients aged 18 years and older with histologically confirmed adenocarcinoma of the distal sigmoid colon, rectosigmoid junction, or rectum, who underwent surgery with primary colorectal anastomosis between May and November 2025. No restrictions regarding tumor stage were applied. Intraoperatively, fluorescence angiography with ICG (0.1 mg/kg) was performed. Perfusion was assessed using the UFF-630/675-01-BIOSPEC system with quantitative analysis of fluorescence parameters, including maximum intensity (Imax), time to peak intensity (Tmax), inflow rate, and outflow rate. The primary outcome was the frequency of discrepancies between visual, qualitative, and quantitative perfusion assessment of the colonic wall. Postoperative complications were recorded within 30 days and classified according to the Clavien-Dindo classification, while anastomotic leakage was graded according to the ISREC classification. RESULTS: a total of 20 patients were included in the study. Impaired colonic wall perfusion was identified in 3/20 (15%) patients based on visual assessment, in 3/20 (15%) patients based on qualitative ICG assessment, whereas quantitative analysis revealed signs of reduced perfusion in 6/20 (30%) patients. Subjective perfusion assessment was based on visual signs of blood supply. The presence of bright red bleeding and a visibly pulsatile blood jet were evaluated. The presence of bright red blood alone was considered a doubtful finding, whereas a pulsatile jet of bright red blood was interpreted as a positive result. In the absence of these signs, additional bowel resection was performed prior to ICG assessment. Thus, a discrepancy between subjective visual and quantitative perfusion assessment was observed in 3/20 (15%) patients, and a similar discrepancy between qualitative ICG assessment and quantitative analysis was also observed in 3/20 (15%) patients. Anastomotic leakage occurred in 2/20 (10%) patients, including 1/20 (5%) case of grade A and 1/20 (5%) case of grade B according to the ISREC classification. In both patients, a decrease in Imax to 83% and 87%, respectively, was observed. In one of these patients, visual perfusion assessment was considered adequate, whereas qualitative ICG assessment was classified as weakly positive in both cases. Negative visual and qualitative perfusion assessments were consistent with quantitative findings in 2/20 (10%) patients. CONCLUSION: the preliminary data demonstrate the presence of discrepancies between subjective, qualitative, and quantitative assessment of intestinal wall perfusion. The clinical significance of these findings should be further evaluated in larger prospective studies.
- Open Access
- 27 February 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (1) , 19-27
Surgical treatment for patients with persistent and recurrent squamous cell anal carcinoma
AIM: to evaluate the oncological and surgical results of the treatment in patients with recurrent squamous cell anal carcinoma (SCAC) after CRT and to identify prognostic factors of overall survival (OS). PATIENTS AND METHODS: patients who underwent abdominoperineal resection (APR) between January 2013 to December 2024 for persistent or recurrent squamous cell carcinoma of the anal canal after CRT were retrospectively analysed in a single-centre study. The early and long-term outcomes, recurrence and incomplete response to CRT were compared. The primary endpoint was overall survival (OS). Additionally, the disease-free survival (DFS), the R0 resection rate, post-op complications, risk factors, second recurrence after APR were evaluated. RESULTS: sixty-one patients underwent APR, of which 34 (55.7%) had a recurrence and 27 (44.3%) had an incomplete response to CRT. The median follow-up was 35.9 months (95% CI: 25.3–46.6). The overall 3-year survival rate was 66.5% (95% CI 54.0–81.9%). The 3-year OS was 74.0% for relapses (95% CI 59.3–93.0%) and 56.4% for incomplete response to CRT (95% CI 37.9–84.0%). The differences in OS were unreliable (HR 1.8; 95% CI: 0.7–4.6; p = 0.2). The 3-year DFS was 55.4% (95% CI 43.2–71.1%). Three-year DFS was 63.1% (95%CI 47.4–83.7%) for relapses and 46.1% (95% CI 29.2–72.5%) for incomplete response to CRT. Differences in DFS were unreliable (HR 1.70; 95% CI: 0.7–4,5%; p = 0.18). Ten (16.1%) patients developed distant metastases after surgery. Sixteen (47.1%) patients developed local recurrence after APR, 2 (12.5%) of them underwent salvage re-operation and another two of them (12.5%) underwent repeated radiation therapy. Seven (43.7%) out of 16 patients received palliative chemotherapy. The remaining 5/16 (31.3%) patients received symptomatic treatment. The median age of patients with recurrent relapse was 23.9 (95% CI 23.7–24.1) months. R0 resection was performed in 55 (90.30%) patients. OS was significantly reduced by incomplete response of the primary tumor to CRT (HR 2.7; 95% CI: 0.98– 7.92; p = 0.05) and violation of the CRT regimen (HR 2.8; 95% CI: 1.03–7.62; р = 0.04). CONCLUSION : surgical treatment of recurrent SCAC is associated with a high risk of second recurrence, but remains the only potentially curative option for this category of patients. It is necessary to find ways to improve local disease control during surgical treatment.
- 27 February 2026
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 25 (1) , 19-27
Open AccessSurgical treatment for patients with persistent and recurrent squamous cell anal carcinoma
AIM: to evaluate the oncological and surgical results of the treatment in patients with recurrent squamous cell anal carcinoma (SCAC) after CRT and to identify prognostic factors of overall survival (OS). PATIENTS AND METHODS: patients who underwent abdominoperineal resection (APR) between January 2013 to December 2024 for persistent or recurrent squamous cell carcinoma of the anal canal after CRT were retrospectively analysed in a single-centre study. The early and long-term outcomes, recurrence and incomplete response to CRT were compared. The primary endpoint was overall survival (OS). Additionally, the disease-free survival (DFS), the R0 resection rate, post-op complications, risk factors, second recurrence after APR were evaluated. RESULTS: sixty-one patients underwent APR, of which 34 (55.7%) had a recurrence and 27 (44.3%) had an incomplete response to CRT. The median follow-up was 35.9 months (95% CI: 25.3–46.6). The overall 3-year survival rate was 66.5% (95% CI 54.0–81.9%). The 3-year OS was 74.0% for relapses (95% CI 59.3–93.0%) and 56.4% for incomplete response to CRT (95% CI 37.9–84.0%). The differences in OS were unreliable (HR 1.8; 95% CI: 0.7–4.6; p = 0.2). The 3-year DFS was 55.4% (95% CI 43.2–71.1%). Three-year DFS was 63.1% (95%CI 47.4–83.7%) for relapses and 46.1% (95% CI 29.2–72.5%) for incomplete response to CRT. Differences in DFS were unreliable (HR 1.70; 95% CI: 0.7–4,5%; p = 0.18). Ten (16.1%) patients developed distant metastases after surgery. Sixteen (47.1%) patients developed local recurrence after APR, 2 (12.5%) of them underwent salvage re-operation and another two of them (12.5%) underwent repeated radiation therapy. Seven (43.7%) out of 16 patients received palliative chemotherapy. The remaining 5/16 (31.3%) patients received symptomatic treatment. The median age of patients with recurrent relapse was 23.9 (95% CI 23.7–24.1) months. R0 resection was performed in 55 (90.30%) patients. OS was significantly reduced by incomplete response of the primary tumor to CRT (HR 2.7; 95% CI: 0.98– 7.92; p = 0.05) and violation of the CRT regimen (HR 2.8; 95% CI: 1.03–7.62; р = 0.04). CONCLUSION : surgical treatment of recurrent SCAC is associated with a high risk of second recurrence, but remains the only potentially curative option for this category of patients. It is necessary to find ways to improve local disease control during surgical treatment.
- Open Access
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 60-68
Analysis of the learning curve for laparoscopic colon resections in a specialized regional clinic
Aim. To investigate the learning curve for laparoscopic colon resections in a specialized regional clinical setting. Materials and methods. Analysis of the data from the Omsk Regional Cancer Registry and the hospital information system of the Omsk Clinical Oncology Center from the period between 2015 and 2023 was performed. The study included patients who underwent laparoscopic colon resections for cancer. Risk-adjusted cumulative sum (RA-CUSUM) method was used to define the stages of mastering the technique. The primary outcome measure was the incidence of severe postoperative complications (Clavien–Dindo grade IIIB and above). Operative time, intraoperative blood loss, conversion rate, length of hospital stay and long-term treatment outcomes were also analyzed. Results. Data from 305 laparoscopic colon resections were included in the analysis. The proportion of laparoscopic procedures increased from 8.9 % in 2015 to 27.8 % in 2023. The learning curve analysis revealed four distinct phases of proficiency acquisition. In the 1st phase (procedures 1–30), the complication risk was 0 %. The 2nd phase (procedures 31–80) was characterized by the highest risk of severe complications at 20.00 % (95 % confidence interval 11.24–33.04). A decrease in risk was observed during the 3rd phase (procedures 81–93). The final, 4th phase (procedures 94–304) achieved consistently low complication risk of 2.84 % (95 % confidence interval 1.31–6.06). The critical point for completing the learning phase was identified at the 93rd procedure. Analysis of the learning curve for conversions revealed the peak conversion rate of 23.1 % during the recovery phase, which subsequently decreased to 2.4 % in the stability phase. The overall conversion rate for the entire series decreased from 11.1 % in 2015 to 6.0 % in 2023. Operative time and intraoperative blood loss remained stable throughout the observation period. The 5-year overall survival rate was 81.6 %, and the recurrence-free survival rate was 81.1 %. Conclusion. The implementation of laparoscopic technologies requires structured training with increase in the number of surgeons performing minimally invasive surgeries. The period of intense learning occurs between the 30th and 80th procedures, after which stable and predictable results are achieved.
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 60-68
Open AccessAnalysis of the learning curve for laparoscopic colon resections in a specialized regional clinic
Aim. To investigate the learning curve for laparoscopic colon resections in a specialized regional clinical setting. Materials and methods. Analysis of the data from the Omsk Regional Cancer Registry and the hospital information system of the Omsk Clinical Oncology Center from the period between 2015 and 2023 was performed. The study included patients who underwent laparoscopic colon resections for cancer. Risk-adjusted cumulative sum (RA-CUSUM) method was used to define the stages of mastering the technique. The primary outcome measure was the incidence of severe postoperative complications (Clavien–Dindo grade IIIB and above). Operative time, intraoperative blood loss, conversion rate, length of hospital stay and long-term treatment outcomes were also analyzed. Results. Data from 305 laparoscopic colon resections were included in the analysis. The proportion of laparoscopic procedures increased from 8.9 % in 2015 to 27.8 % in 2023. The learning curve analysis revealed four distinct phases of proficiency acquisition. In the 1st phase (procedures 1–30), the complication risk was 0 %. The 2nd phase (procedures 31–80) was characterized by the highest risk of severe complications at 20.00 % (95 % confidence interval 11.24–33.04). A decrease in risk was observed during the 3rd phase (procedures 81–93). The final, 4th phase (procedures 94–304) achieved consistently low complication risk of 2.84 % (95 % confidence interval 1.31–6.06). The critical point for completing the learning phase was identified at the 93rd procedure. Analysis of the learning curve for conversions revealed the peak conversion rate of 23.1 % during the recovery phase, which subsequently decreased to 2.4 % in the stability phase. The overall conversion rate for the entire series decreased from 11.1 % in 2015 to 6.0 % in 2023. Operative time and intraoperative blood loss remained stable throughout the observation period. The 5-year overall survival rate was 81.6 %, and the recurrence-free survival rate was 81.1 %. Conclusion. The implementation of laparoscopic technologies requires structured training with increase in the number of surgeons performing minimally invasive surgeries. The period of intense learning occurs between the 30th and 80th procedures, after which stable and predictable results are achieved.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500602
Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer
PURPOSE: Although adjuvant chemotherapy is standard for locally advanced colon cancer, defective mismatch repair (dMMR)/microsatellite instability (MSI) tumors show high sensitivity to immune checkpoint inhibitors. We aimed to investigate the efficacy of the PD-1 inhibitor prolgolimab in this setting. METHODS: We conducted phase II nonrandomized open-label clinical trial (ClinicalTrials.gov identifier: NCT06428487 ) in patients with locally advanced colorectal cancer (CRC) and dMMR/MSI. Prolgolimab (1 mg/kg) was administered once every 2 weeks, and surgery was performed after 6 months of immunotherapy. In case of surgical treatment refusal, the systemic treatment proceeded for 1 year. The primary end point was the rate of pathologic complete response (pCR, in operated cases) + clinical complete response (cCR, in nonoperated cases). Secondary end points included pCR, major pathologic response (MPR), objective response (ORR) rates, safety, disease-free survival (DFS), and overall survival. RESULTS: Of the 30 enrolled, 26 (86.6%) patients underwent surgery after the end of immunotherapy. The study met its primary end point, with 17 (56.7%) of 30 patients achieving pCR (n = 16) + cCR (n = 1 as nonoperated case). According to histologic examination, an MPR (TRG 1-2) was observed in 21 (80.8%) of 26 patients, including 16 (61.6%) patients with pCR. Radiographic ORR was 89.7%, and cCR was observed in six cases (20.7%, five patients underwent surgery further). Three patients with low rectal primary tumors refused to undergo a surgical treatment. The median follow-up was 19 months (range, 13-32). The 18-month DFS was 90%: two progressions and one unrelated death were detected. Grade 3-4 immune-related adverse effects were recorded in one (3.3%) patient. CONCLUSION: The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500602
Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer
PURPOSE: Although adjuvant chemotherapy is standard for locally advanced colon cancer, defective mismatch repair (dMMR)/microsatellite instability (MSI) tumors show high sensitivity to immune checkpoint inhibitors. We aimed to investigate the efficacy of the PD-1 inhibitor prolgolimab in this setting. METHODS: We conducted phase II nonrandomized open-label clinical trial (ClinicalTrials.gov identifier: NCT06428487 ) in patients with locally advanced colorectal cancer (CRC) and dMMR/MSI. Prolgolimab (1 mg/kg) was administered once every 2 weeks, and surgery was performed after 6 months of immunotherapy. In case of surgical treatment refusal, the systemic treatment proceeded for 1 year. The primary end point was the rate of pathologic complete response (pCR, in operated cases) + clinical complete response (cCR, in nonoperated cases). Secondary end points included pCR, major pathologic response (MPR), objective response (ORR) rates, safety, disease-free survival (DFS), and overall survival. RESULTS: Of the 30 enrolled, 26 (86.6%) patients underwent surgery after the end of immunotherapy. The study met its primary end point, with 17 (56.7%) of 30 patients achieving pCR (n = 16) + cCR (n = 1 as nonoperated case). According to histologic examination, an MPR (TRG 1-2) was observed in 21 (80.8%) of 26 patients, including 16 (61.6%) patients with pCR. Radiographic ORR was 89.7%, and cCR was observed in six cases (20.7%, five patients underwent surgery further). Three patients with low rectal primary tumors refused to undergo a surgical treatment. The median follow-up was 19 months (range, 13-32). The 18-month DFS was 90%: two progressions and one unrelated death were detected. Grade 3-4 immune-related adverse effects were recorded in one (3.3%) patient. CONCLUSION: The use of prolgolimab in locally advanced dMMR/MSI CRC is associated with high rates of pCR and cCR, allowing for further exploration of organ-sparing approaches in these patients.
- Open Access
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Treatment-Related Toxicity in Combined-Modality Therapy for Intermediate-Risk Rectal Cancer
Введение. Применение неоадъювантной термохимиолучевой терапии в комбинированном лечении рака прямой кишки со средним риском прогрессирования обусловлено высокой частотой рецидивов и низкими показателями безрецидивной выживаемости при использовании только одной неоадъювантной лучевой терапии и позволяет уменьшить частоту рецидивов рака с 8,4 до 0,7 % и увеличить пятилетнюю безрецидивную выживаемость с 60,3 до 81,3 %. Однако оно приводит к увеличению частоты и степени тяжести токсических проявлений. В проведенных ранее исследованиях была изучена лишь общая характеристика токсических проявлений без детализации их структуры. Цель. Изучить характер и частоту токсических проявлений при комплексной терапии у больных раком прямой кишки среднего риска прогрессирования при использовании «короткого» курса неоадъювантной термохимиолучевой терапии. Материалы и методы. Проанализированы токсические проявления у 337 больных раком прямой кишки со средним риском прогрессирования. У 190 пациентов проводилась неоадъювантная лучевая терапия «коротким» курсом облучения по 5 Гр до СОД 25 Гр, а у 147 — комбинированное лечение с модуляцией эффекта лучевой терапии тремя разнонаправленными радиомодификаторами: трехкратной локальной сверхвысокочастотной гипертермией на аппаратах «Яхта-3» или «Яхта-4», двукратным внутриректальным подведением к опухоли биополимерной композиции с метронидазолом (10 г/м2) перед 3-м и 5-м сеансом облучения и двухнедельным пероральным приемом капецитабина в суточной дозе 2,0 г/м2. Операции выполнялись через 4-6 нед. после завершения курса облучения. Результаты. Токсические проявления диагностированы у 25 (13,2 %) из 190 пациентов, проходивших лучевую терапию в монорежиме, и у 46 (31,3 %) из 147 больных, получивших терморадиохимиотерапию (p = 0,00001). В группе терморадиохимиотерапии преобладала гастроинтестинальная токсичность, которая диагностирована в 36,7 % (у 54 из 147) наблюдений, в то время как при лучевой терапии в монорежиме превалировала гематологическая токсичность у 10,5 % (у 20 из 190) больных. Заключение. Несмотря на увеличение частоты токсических проявлений у больных в группе среднего риска прогрессирования заболевания при использовании неоадъювантной термохимиолучевой терапии, у всех пациентов удалось завершить запланированное лечение в полном объеме и достигнуть улучшения отдаленных результатов лечения по сравнению с одной неоадъювантной лучевой терапией.
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Open AccessTreatment-Related Toxicity in Combined-Modality Therapy for Intermediate-Risk Rectal Cancer
Введение. Применение неоадъювантной термохимиолучевой терапии в комбинированном лечении рака прямой кишки со средним риском прогрессирования обусловлено высокой частотой рецидивов и низкими показателями безрецидивной выживаемости при использовании только одной неоадъювантной лучевой терапии и позволяет уменьшить частоту рецидивов рака с 8,4 до 0,7 % и увеличить пятилетнюю безрецидивную выживаемость с 60,3 до 81,3 %. Однако оно приводит к увеличению частоты и степени тяжести токсических проявлений. В проведенных ранее исследованиях была изучена лишь общая характеристика токсических проявлений без детализации их структуры. Цель. Изучить характер и частоту токсических проявлений при комплексной терапии у больных раком прямой кишки среднего риска прогрессирования при использовании «короткого» курса неоадъювантной термохимиолучевой терапии. Материалы и методы. Проанализированы токсические проявления у 337 больных раком прямой кишки со средним риском прогрессирования. У 190 пациентов проводилась неоадъювантная лучевая терапия «коротким» курсом облучения по 5 Гр до СОД 25 Гр, а у 147 — комбинированное лечение с модуляцией эффекта лучевой терапии тремя разнонаправленными радиомодификаторами: трехкратной локальной сверхвысокочастотной гипертермией на аппаратах «Яхта-3» или «Яхта-4», двукратным внутриректальным подведением к опухоли биополимерной композиции с метронидазолом (10 г/м2) перед 3-м и 5-м сеансом облучения и двухнедельным пероральным приемом капецитабина в суточной дозе 2,0 г/м2. Операции выполнялись через 4-6 нед. после завершения курса облучения. Результаты. Токсические проявления диагностированы у 25 (13,2 %) из 190 пациентов, проходивших лучевую терапию в монорежиме, и у 46 (31,3 %) из 147 больных, получивших терморадиохимиотерапию (p = 0,00001). В группе терморадиохимиотерапии преобладала гастроинтестинальная токсичность, которая диагностирована в 36,7 % (у 54 из 147) наблюдений, в то время как при лучевой терапии в монорежиме превалировала гематологическая токсичность у 10,5 % (у 20 из 190) больных. Заключение. Несмотря на увеличение частоты токсических проявлений у больных в группе среднего риска прогрессирования заболевания при использовании неоадъювантной термохимиолучевой терапии, у всех пациентов удалось завершить запланированное лечение в полном объеме и достигнуть улучшения отдаленных результатов лечения по сравнению с одной неоадъювантной лучевой терапией.